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Cardiovascular Manifestations of
Hyperthyroidism Before and After Antithyroid Therapy
A Matched Case-Control Study
Faizel Osman, MD, MRCP, Jayne A. Franklyn, MD, PHD, FRCP, Roger L. Holder, BSC,
Michael C. Sheppard, PHD, FRCP, Michael D. Gammage, MD, FRCP, FESC
Birmingham, England
Objectives This study sought to prospectively evaluate the prevalence of cardiovascular abnormalities in patients with overt
hyperthyroidism before and after antithyroid therapy.
Background Overt hyperthyroidism is associated with recognized cardiovascular effects believed to be reversed by antithyroid
therapy; however, increasing data suggest significant long-term cardiovascular mortality.
Methods A total of 393 (312 women, 81 men) consecutive unselected patients with overt hyperthyroidism were recruited
and compared with 393 age- and gender-matched euthyroid control subjects. Hyperthyroid patients were re-
evaluated after antithyroid therapy. Findings in patients and matched control subjects were compared at presen-
tation, after treatment when patients had subclinical hyperthyroidism biochemically, and when patients were
rendered biochemically euthyroid. All had a structured cardiovascular history and examination, including mea-
surements of blood pressure (BP) and pulse rate. All had resting 12-lead electrocardiogram and 24-h digital
Holter monitoring of cardiac rhythm.
Results A higher prevalence of cardiovascular symptoms and signs, as well as abnormal hemodynamic parameters, was
noted among hyperthyroid patients at recruitment compared with control subjects. Cardiac dysrhythmias, espe-
cially supraventricular, were more prevalent among patients than among control subjects. Palpitation and dys-
pnea, postural decrease in systolic pressure, and atrial fibrillation (AF) remained more prevalent in treated hy-
perthyroid subjects with subclinical hyperthyroidism compared with control subjects, and remained more
prevalent after restoration of euthyroidism. Predictors for successful reversion to sinus rhythm in those with AF
associated with hyperthyroidism were lower BP measurements at recruitment and an initial hypothyroid state
induced by antithyroid therapy. Mortality was higher in hyperthyroid subjects than in control subjects after a
mean period of follow-up of 66.6 months.
Conclusions Cardiovascular abnormalities are common in patients with overt hyperthyroidism at presentation, but some per-
sist despite effective antithyroid therapy. (J Am Coll Cardiol 2007;49:71–81) © 2007 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.042y
r
o
t
a
s
b
c
m
n
d
a
pyperthyroidism is a common disorder with prominent
ardiovascular effects including sinus tachycardia, systolic
ypertension, changes in ventricular systolic and diastolic
unction, changes in peripheral vascular resistance, and
redisposition to dysrhythmias, especially atrial fibrillation
AF) (1). In contrast with overt hyperthyroidism, the
linical impact of subclinical hyperthyroidism (low serum
hyrotropin [TSH] with serum-free thyroxin [T4]/serum-
ree tri-iodothyronine [T3] within the reference range) has
rom the Division of Medical Sciences, University of Birmingham, Edgbaston,
irmingham, England. Dr. Osman was supported by a British Heart Foundation
unior Research Fellowship.n
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ccepted August 17, 2006.et to be established, and treatment of subclinical hyperthy-
oidism remains controversial (2). The clinical significance
f subclinical hyperthyroidism in those who have received
reatment for overt hyperthyroidism is unknown.
Despite the perception that hyperthyroidism is reversible
nd without long-term consequences, increasing evidence
uggests that it is associated with significant vascular mor-
idity and mortality after effective treatment (3–5), even in
ontemporary cohorts (6); persisting cardiovascular abnor-
alities may contribute to this vascular mortality. To date,
o large prospective controlled study has defined the car-
iovascular manifestations of hyperthyroidism before and
fter antithyroid therapy. The current study evaluated the
revalence of cardiovascular symptoms and signs, hemody-
amic abnormalities, and dysrhythmias in overt hyperthy-
m
h
u
i
p
h
c
3
t
s
t
h
g
t
w
m
t
w
a
w
d
g
c
r
f
r
H
2
H
t
g
w
r
r
m
P
h
d
c
e
s
w
m
w
N
m
d
t
C
w
p
b
i
p
c
h
e
r
o
w
F
v
d
v
t
a
m
(
s
s
s
s
s
C
w
o
b
a
u
m
p
c
m
s
s
t
8
v
72 Osman et al. JACC Vol. 49, No. 1, 2007
Cardiovascular Manifestations of Hyperthyroidism January 2/9, 2007:71–81roidism before and after antithy-
roid therapy and compared
findings with euthyroid control
subjects. To examine the specific
influence of hyperthyroidism in
the absence of underlying vascu-
lar disease, we also analyzed find-
ings excluding all subjects with
known vascular disease (cardio-
vascular, cerebrovascular, or pe-
ripheral vascular). Mortality data
were obtained on all subjects and
compared between the hyperthy-
roid and control cohorts.
Methods
Subjects and study protocol. All
patients referred to our Thyroid
Clinic, University Hospital Bir-
ingham, England, with a confirmed diagnosis of overt
yperthyroidism were eligible, enabling us to recruit a large
nselected cohort. Overt hyperthyroidism was defined as
ncreased serum-free T4 and/or T3 concentration in the
resence of an undetectable TSH level. Patients with overt
yperthyroidism of any etiology were investigated and were
ategorized by simple clinical and immunologic criteria into
diagnostic groups (7): Graves disease (biochemical hyper-
hyroidism with 2 of the following: palpable diffuse goiter,
ignificant titer of thyroid peroxidase/thyroglobulin autoan-
ibodies, presence of dysthyroid eye disease), toxic nodular
yperthyroidism (hyperthyroidism with palpable nodular
oiter), and hyperthyroidism of indeterminate etiology (nei-
her criteria fulfilled). Hyperthyroid subjects were treated
ith antithyroid drugs/radioiodine (8). An age- and gender-
atched euthyroid control group, free of past or current
hyroid dysfunction, was recruited from staff members
orking at the hospital or medical school or their relatives
nd from a local community center; the latter represented a
ide spectrum of the elderly community, both affluent and
isadvantaged, attending for social reasons. The control
roup had the same investigations as the hyperthyroid
ohort. Approval for the study was obtained from the local
esearch ethics committee, and all subjects provided in-
ormed consent.
All had a structured cardiovascular history and examination,
esting 12-lead electrocardiogram (ECG) (Pagewriter 200,
ewlett-Packard, Palo Alto, California), digital ambulatory
4-h Holter monitoring (Life Card CF, Reynolds Medical,
ertford, England), and assessment of thyroid function using
he Bayer ACS 180/Advia Centaur System (Newbury, En-
land). Normal ranges for serum-free T4, T3, and TSH
ere 9 to 20 pmol/l, 3.5 to 6.5 pmol/l, and 0.5 to 5.0 mU/l,
espectively.
Hyperthyroid patients (but not control subjects) were
Abbreviations
and Acronyms
AF  atrial fibrillation
BP  blood pressure
ECG  electrocardiogram
IQR  interquartile range
LVH  left ventricular
hypertrophy
nsVT  nonsustained
ventricular tachycardia
PAF  paroxysmal atrial
fibrillation
SVT  supraventricular
tachycardia
T4  thyroxin
T3  tri-iodothyronine
TSH  thyrotropine-evaluated after antithyroid therapy with repeat assess- aent at approximately 6 and 9 months after recruitment.
atients found to show the biochemistry of subclinical
yperthyroidism (suppressed TSH with normal free T4/T3)
uring antithyroid therapy were compared with matched
ontrol subjects. Similarly, those rendered biochemically
uthyroid at follow-up were compared with matched control
ubjects. Those patients found to have AF at presentation
ere followed up to evaluate the course of their dysrhyth-
ia. A further analysis was performed confined to subjects
ithout known vascular disease.
All subjects were registered with the UK Office for
ational Statistics as described before (3,6) to obtain
ortality data during follow-up. The underlying cause of
eath was coded according to the International Classifica-
ion of Diseases (9).
ardiovascular history and examination. Information
as collected using a structured questionnaire derived from
revious studies (10,11). Cardiovascular symptoms had to
e of new onset coincident with the onset of hyperthyroid-
sm. Specific symptoms evaluated included dyspnea, chest
ain, palpitation, orthopnea, paroxysmal nocturnal dyspnea,
ough, and pedal edema. History of vascular disease (treated
ypertension, ischemic heart disease, cerebrovascular dis-
ase, congestive cardiac failure) and diabetes mellitus were
ecorded, as was a family history of vascular disease in first-
r second-degree relatives 70 years old. Smoking history
as documented as never, previous, or current smoker.
indings noted on examination included presence of raised
enous pressure (2 cm above sternal notch at 45°),
isplaced apex beat (beyond 5th intercostal space, midcla-
icular line), cardiac murmurs, and abnormal chest auscul-
ation (crepitations or wheeze). Resting pulse rate, and lying
nd standing (after 5 min) blood pressure (BP) measure-
ents were taken, the latter with an automatic monitor
Dinamap Pro200, GE Systems, Miami, Florida). The
ystolic pressure difference was calculated as standing-lying
ystolic pressure, diastolic pressure difference as lying-
tanding diastolic pressure, and pulse rate change as
tanding-lying heart rate. All subjects were evaluated by a
ingle investigator (F.O.).
ardiac rhythm assessment. The ECG abnormalities
ere coded using the Minnesota classification (12); presence
f pathological Q waves, abnormal cardiac axis, left or right
undle branch block, left ventricular hypertrophy (LVH),
nd heart block were noted. All Holter data were analyzed
sing the Pathfinder 700 Analyzer (Reynolds Medical) and
anually edited to correct inaccuracies. Presence of 240
remature atrial or ventricular ectopic beats/24-h period was
lassified as significant (13). Atrial salvoes were defined as
ore than 3 consecutive premature atrial beats (14) and
upraventricular tachycardia (SVT) as 10 consecutive
upraventricular premature beats (15). Nonsustained ven-
ricular tachycardia (nsVT) was defined as more than
consecutive ventricular ectopic beats lasting 30 s and
entricular salvoes as 4 to 8 consecutive ectopic beats,
llowing detection of short and long bursts of ventricular
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ned as consecutive ventricular beats lasting 30 s (16).
he number of isolated ventricular and atrial premature
eats was evaluated, along with the presence of second- or
hird-degree heart block.
tatistical analysis. All data were analyzed using SPSS
or Windows version 12.0 (SPSS Inc., Chicago, Illinois);
ests of normality were performed using Minitab version
3.0 (Minitab Inc., State College, Pennsylvania). Con-
inuous variables assuming a normal distribution (pulse
ate, BP) were expressed as mean  SEM; those with a
on-normal distribution (age, serum-free T4/T3) were
xpressed as median  interquartile range (IQR). Nom-
nal data were presented as number and percentage of
otal. Comparisons between nonparametric matched data
ere made using the Wilcoxon signed rank (continuous
ata) and McNemar tests (nominal data). Comparisons
etween normally distributed matched data were made
sing the paired t test. Multivariate conditional logistic
egression analysis (forward selection) was used to iden-
ify independent risk predictors for cardiovascular symp-
oms and rhythm abnormalities. Bonferroni corrections
ere made to significance levels where multiple compar-
sons were used (17); the latter included all comparisons
f cardiovascular symptoms, hemodynamic parameters,
nd rhythm analysis.
esults
aseline characteristics. A total of 396 unselected consec-
tive patients with overt hyperthyroidism were eligible,
f whom 393 were recruited (April 1999 to April 2002);
declined to participate. Those recruited were age-matched
within 2 years) and gender-matched to euthyroid control
ubjects (312 women, 81 men); 180 were recruited from staff
embers or their relatives, 213 from the community center.
edian age of the hyperthyroid and control cohorts was
omparison of Baseline Characteristics Between the Hyperthyroid
Table 1 Comparison of Baseline Characteristics Between the H
Total Cohort
Thyroid
n  393
Control
n  393
Age at recruitment (yrs) 49.0 (36–63) 49.0 (35–63)
Male 81 81
Female 312 312
Undetectable thyrotropin 393 0
Serum-free T4 (pmol/l) 37.5 (27–52) 13.8 (13–15)
Serum-free T3 (pmol/l) 11.4 (8–18) Not measured
Known vascular disease 73 (19%) 71 (18%)
Diabetes mellitus 23 (6%) 11 (3%)
Family history of vascular disease 269 (68%) 278 (71%)
Smoking history
Current smoker 115 (29%) 58 (15%)
Never smoked 148 (38%) 218 (55%)
Past smoker 130 (33%) 117 (30%)Values expressed as median with interquartile-range or n (%). †Excludes those without a matched euth
T3  tri-iodothyronine; T4  thyroxin.imilar (49.0 years: IQR 36 to 63 years vs. 49.0 years: IQR
5 to 63 years, p  0.9); age range 17 to 89 years for both
roups. A total of 233 hyperthyroid patients received
adioiodine, and 378 received carbimazole/propylthiouracil.
f the 393 patients recruited, 147 had Graves disease, 88
ad toxic nodular goiter, and 158 had hyperthyroidism of
ndeterminate origin. Median serum-free T4 and T3 at
iagnosis in the hyperthyroid cohort were 37.5 pmol/l (IQR
7 to 52 pmol/l) and 11.4 pmol/l (IQR 8 to 18 pmol/l),
espectively; serum TSH was undetectable in all. Serum-
ree T4 and TSH were within the normal range for all
ontrol subjects (median 13.8 pmol/l, IQR 13 to 15 pmol/l
s. 1.6 mU/l, IQR 1 to 2 mU/l, respectively). The preva-
ence of vascular diseases was similar between the 2 cohorts;
here were more current smokers in the hyperthyroid cohort
nd fewer never smokers than control subjects. After ex-
luding all patients with known vascular disease, there were
20 hyperthyroid subjects; of these, 266 had matched
ontrol subjects without vascular disease available for com-
arison (Table 1).
A total of 110 showed the biochemistry of subclinical
yperthyroidism when evaluated during follow-up (27.1 
.1 weeks after first evaluation; 92 women, 18 men). The
edian serum-free T4 and T3 were 16.4 pmol/l, IQR 15 to
9 pmol/l and 5.5 pmol/l, IQR 5 to 6 pmol/l, and TSH was
ndetectable in all. A total of patients were rendered
iochemically euthyroid at the time of re-evaluation (36.9
.6 weeks after recruitment; 163 women, 44 men). The
edian serum-free T4 and T3 were 12.8 pmol/l, IQR 11 to
5 pmol/l and 4.1 pmol/l, IQR 3 to 5 pmol/l; all had normal
SH (median 1.8 mU/l, IQR 0.8 to 3.1 mU/l). Compari-
ons of these patients were made with their respective
ontrol subjects. Baseline characteristics of those patients
ost to follow-up (n  69) or not re-evaluated when
ubclinically hyperthyroid or euthyroid after treatment were
ot different compared with those undergoing repeat eval-
ontrol Cohorts*
thyroid and Control Cohorts*
Cohort Without Vascular Disease
p Value
Thyroid†
n  266
Control
n  266 p Value
0.9 42.0 (32–52) 42.0 (33–53) 0.9
53 53
213 213
266 0
36.2 (25–49) 14.0 (13–15)
11.1 (8–17) Not measured
0.9 0 0
0.1 9 (3%) 2 (1%) 0.1
0.7 181 (68%) 189 (71%) 0.6
0.0001 89 (33%) 39 (15%) 0.0001
0.0001 102 (38%) 157 (59%) 0.0001
0.3 75 (28%) 70 (26%) 0.7and C
yperyroid control.
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Cardiovascular Manifestations of Hyperthyroidism January 2/9, 2007:71–81ation in terms of age, gender, known vascular disease, and
iabetes (data not shown).
ardiovascular symptoms and signs. Cardiovascular symp-
oms and signs (Table 2) were more prevalent in hyperthy-
oid patients when first evaluated compared with matched
ontrol subjects, especially palpitation, which was the most
revalent. Comparison of findings from treated patients
ith subclinical hyperthyroidism and their control subjects
howed persistent palpitation, dyspnea, and cough. Palpita-
ion and dyspnea persisted even at assessment after restora-
ion of biochemical euthyroidism. After excluding all sub-
ects with known vascular disease, cardiovascular symptoms
emained more prevalent among hyperthyroid patients at
ecruitment compared with control subjects. Symptoms,
otably palpitation and dyspnea, were also more prevalent
ompared with control subjects in subjects evaluated when
ubclinically hyperthyroid and when rendered euthyroid.
Multivariate logistic regression analysis identified inde-
endent predictors of cardiovascular symptoms both at
ecruitment and after restoration of euthyroidism. Age 50
ears (p  0.0001), female gender (p  0.002), and
erum-free T430 pmol/l (p 0.01) all predicted palpitation
t recruitment. Dyspnea at recruitment was predicted by past
istory of angina (p  0.001) and congestive cardiac failure
p  0.0001), as well as lying diastolic BP 90 mm Hg at
omparison of Cardiovascular Symptoms Between Hyperthyroid an
Table 2 Comparison of Cardiovascular Symptoms Between Hyp
Findings
Total Cohort
Thyroid Cohort
n (%)
Control Cohort
n (%)
Recruitment 393 393
Palpitation 288 (73) 79 (20)
Chest pain 97 (25) 42 (11)
Dyspnea 236 (60) 53 (14)
Cough 137 (35) 45 (12)
Orthopnea 24 (6) 4 (1)
Displaced apex 14 (4) 4 (1)
Cardiac murmur 59 (15) 21 (5)
Chest wheeze/crepitus 36 (9) 6 (2)
SCH follow-up 110 110
Palpitation 49 (45) 20 (18)
Chest pain 15 (14) 12 (11)
Dyspnea 26 (24) 16 (15)
Cough 22 (20) 12 (11)
Orthopnea 4 (4) 1 (1)
Displaced apex 1 (1) 1 (1)
Cardiac murmur 9 (8) 6 (5)
Chest wheeze/crepitus 2 (2) 2 (2)
Euthyroid follow-up 207 207
Palpitation 64 (31) 43 (21)
Chest pain 32 (16) 22 (11)
Dyspnea 61 (30) 27 (13)
Orthopnea 7 (3) 4 (2)
Displaced apex beat 1 (0.5) 3 (1)
Cardiac murmur 16 (8) 13 (6)
Chest wheeze/crepitus 9 (4) 5 (2)CH  subclinical hyperthyroidism.ecruitment (p  0.01). Past history of congestive cardiac
ailure and ischemic heart disease (both p  0.01) predicted
ersisting chest pain and dyspnea after restoration of euthy-
oidism. Past history of vascular disease (p  0.0001),
emale gender (p  0.01), and age 50 years (p  0.001)
lso predicted cardiac symptoms among euthyroid control
ubjects. After excluding those with known vascular disease,
ge 50 years (p  0.005) and female gender (p  0.01)
ndependently predicted palpitation at recruitment among
yperthyroid patients; female gender (p 0.001) and serum
4 30 pmol/l (p  0.005) were predictive of dyspnea at
ecruitment, and current smoking (p  0.05) predicted
ersisting dyspnea after restoration of euthyroidism. The
tiology of hyperthyroidism was not predictive of the
resence of cardiac symptoms either at presentation or after
ntithyroid therapy (data not shown).
emodynamic findings. Resting pulse rate and lying sys-
olic BP were higher in hyperthyroid patients at recruitment
ompared with matched control subjects (82  1 beats/min
s. 73  1 beats/min, p  0.0001, and 137  1 mm Hg vs.
29  1 mm Hg, p  0.0001) (Table 3). A postural
ecrease in systolic pressure was noted in hyperthyroid
atients compared with control subjects (4  1 mm Hg
s. 2 1 mm Hg, p 0.0001). Resting pulse rate and lying
ystolic BP remained higher among patients with subclinical
trol Cohorts
roid and Control Cohorts
Cohort Without Vascular Disease
p Value
Thyroid Cohort
n (%)
Control Cohort
n (%) p Value
266 266
0.0001 199 (75) 52 (20) 0.0001
0.0001 63 (24) 28 (11) 0.0001
0.0001 154 (58) 33 (12) 0.0001
0.0001 83 (31) 32 (12) 0.0001
0.0001 9 (3) 2 (1) 0.07
0.01 6 (2) 0 0.05
0.0001 32 (12) 15 (6) 0.01
0.0001 18 (7) 2 (1) 0.0001
72 72
0.0001 33 (46) 14 (19) 0.002
0.4 9 (13) 6 (8) 0.6
0.002 19 (26) 13 (18) 0.3
0.05 14 (19) 6 (8) 0.1
0.1 3 (4) 1 (1) 0.6
0.9 1 (1) 0 0.9
0.1 5 (7) 2 (3) 0.5
0.9 1 (1) 0 0.9
133 133
0.0007 45 (34) 27 (20) 0.03
0.2 17 (13) 17 (13) 0.9
0.0001 37 (28) 17 (13) 0.005
0.5 3 (2) 2 (2) 0.9
0.6 0 0 0.9
0.7 7 (5) 8 (6) 0.9
0.4 3 (2) 2 (2) 0.9d Con
erthy
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beats/min vs. 73  1 beats/min, p  0.01, and 137  2
m Hg vs. 130  1 mm Hg, p  0.01); the postural
ecrease in systolic pressure also persisted (3  1 mm Hg
s. 1  1 mm Hg, p  0.005). No differences in hemody-
amic parameters remained at the euthyroid assessment
xcept the postural decrease in systolic pressure (2  1
m Hg vs. 3  1 mm Hg, p  0.0001). Excluding those
ith vascular disease, findings for BP and resting pulse rate
emained unchanged at recruitment and subclinical/
uthyroid follow-up; the postural decrease in systolic pres-
ure among patients persisted but was no longer significant
t follow-up.
ardiac rhythm analysis. One hyperthyroid subject had a
ermanent pacemaker and was excluded from analysis.
yperthyroid subjects at presentation showed a higher
revalence of AF on ECG compared with control subjects
Table 4). Of the 392 patients investigated by Holter
onitor, 333 (85%) had analyzable data; 311 of these were
sed in matched comparison with control subjects. The
inimum, mean, and maximum 24-h heart rates were
igher among patients. The prevalence of AF and atrial
alvoes was higher in patients than in control subjects, but
ther dysrhythmias were similar. After excluding those with
nown vascular disease, AF and atrial salvoes were still more
revalent among hyperthyroid patients than among control
ubjects.
Of the 110 patients with subclinical hyperthyroidism
omparison of Hemodynamic Parameters Between Hyperthyroid an
Table 3 Comparison of Hemodynamic Parameters Between Hyp
Parameter
Total Cohort
Thyroid
Mean  SEM
Control
Mean  SEM
Recruitment 393 393
Resting pulse rate 82 1 73 1
Lying systolic pressure 137 1 129 1
Lying diastolic pressure 76 1 75 1
Pulse rate change 6 4 4 1
Systolic pressure difference 4 1 2 1
Diastolic pressure difference 4 1 4 1
SCH follow-up 110 110
Resting pulse rate 76 1 73 1
Lying systolic pressure 137 2 130 1
Lying diastolic pressure 76 1 75 1
Pulse rate change 9 2 7 1
Systolic pressure difference 3 1 1 1
Diastolic pressure difference 3 1 4 1
Euthyroid follow-up 207 207
Resting pulse rate 73 1 73 1
Lying systolic pressure 134 2 131 1
Lying diastolic pressure 74 1 75 1
Pulse rate change 11 4 5 2
Systolic pressure difference 2 1 3 1
Diastolic pressure difference 5 1 4 1
ulse rates measured in beats/min, blood pressures in mm Hg.
SCH  subclinical hyperthyroidism.uring follow-up, 1 had a permanent pacemaker and was (xcluded from analysis. Patients had a higher prevalence of
F on ECG compared with control subjects. A total of 88
atients (81%) had analyzable Holter data; 85 were matched
ith control subjects. The prevalence of AF on Holter and
inimum heart rate remained higher compared with con-
rol subjects; differences were no longer apparent after
xcluding those with vascular disease (Table 5).
One of the 207 patients rendered biochemically euthyroid
t follow-up had a permanent pacemaker and was excluded
rom analysis. Comparison of the remaining 206 matched
atient-control data showed a higher prevalence of AF on
CG in euthyroid patients than in control subjects. A total
f 146 (71%) patients had analyzable Holter data; 133 were
atched with control subjects. Comparison of Holter data
howed no differences between the 2 groups; however, not
ll patients found to have AF on ECG had Holter data
vailable at this comparison. Excluding those with vascular
isease showed no differences in prevalence of ECG or
olter data between patients and control subjects (Table 6).
Independent predictors of dysrhythmias at recruitment
ncluded age 50 years (atrial salvoes, significant atrial or
entricular ectopic beats, p  0.0001), known vascular
isease (ventricular salvoes, p  0.05), diastolic BP 90
m Hg at recruitment (nsVT, p  0.03), and increased
enous pressure (SVT, p  0.002). Independent predictors
f persisting dysrhythmias at euthyroidism included age
50 years (atrial salvoes, p  0.005), serum-free T4 40
mol/l at presentation (nsVT, p  0.05), and diabetes
trol Cohorts
roid and Control Cohorts
Cohort Without Vascular Disease
p Value
Thyroid
Mean  SEM
Control
Mean  SEM p Value
266 266
0.0001 81 1 73 1 0.0001
0.0001 131 1 127 1 0.009
0.7 74 1 74 1 0.7
0.5 6 4 3 2 0.5
0.0001 2 1 2 1 0.0001
0.9 5 1 4 1 0.4
72 72
0.01 76 1 72 1 0.05
0.01 132 3 126 2 0.05
0.8 75 2 74 1 0.6
0.4 5 1 1 0.1
0.005 2 1 1 1 0.08
0.5 3 1 3 1 0.9
133 133
0.9 72 2 73 1 0.7
0.1 128 2 128 2 0.9
0.4 73 1 73 1 0.9
0.2 11 4 5 2 0.6
0.005 1 1 2 1 0.4
0.6 5 1 5 1 0.8d Con
erthySVT, p  0.01). Etiology of hyperthyroidism was not
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Cardiovascular Manifestations of Hyperthyroidism January 2/9, 2007:71–81redictive of the presence of dysrhythmias either at presen-
ation or after antithyroid therapy (data not shown).
se of drugs affecting cardiac rate or rhythm. No subjects
ere prescribed class I antiarrhythmic therapy or amioda-
one, and no differences were noted in use of class IV drugs
verapamil, diltiazem) at recruitment or subsequent follow-
p. Use of beta-blockers was more frequent in hyperthyroid
atients at recruitment and subclinical hyperthyroidism
ompared with control subjects (25% vs. 6%, p  0.0001
nd 19% vs. 5%, p  0.0001, respectively). Use of sotalol
hen patients were rendered euthyroid was higher than in
ontrol subjects (3% vs. 0.5%, p  0.01). Digoxin use was
igher among patients at recruitment and at subclinical
yperthyroid and euthyroid follow-up compared with con-
rol subjects (4% vs. 0.2%, p  0.0001; 4% vs. 1%, p 
.005; 4% vs. 0.5%, p  0.0001, respectively). Further
omparisons excluding all subjects prescribed these drugs
id not affect any of the overall cardiovascular findings at
ecruitment, during subclinical hyperthyroidism, or during
uthyroid follow-up (table available on request).
F and hyperthyroidism. Twenty-nine patients (7.3%)
ere found to have AF at recruitment, of whom 21 had
ewly diagnosed AF (15 persistent AF, 6 paroxysmal atrial
brillation [PAF]), and 8 previously known persistent or
ermanent AF (all euthyroid at original diagnosis). Patients
ith AF were older than those without (69.0 years, IQR 65
o 76 years vs. 49.5 years, IQR 36 to 63 years, p  0.0001)
nd had a higher prevalence of known vascular disease (51%
omparison of Electrocardiogram and Holter Data of Hyperthyroid P
Table 4 Comparison of Electrocardiogram and Holter Data of H
Electrocardiogram Findings
Total Coho
Thyroid
n  392
Control
n  392
AF 24 (6%) 3 (0.8%
Abnormal cardiac axis 21 (5%) 17 (4%)
Left ventricular hypertrophy 7 (2%) 1 (0.3%
Right bundle branch block 7 (2%) 8 (2%)
Left bundle branch block 2 (0.5%) 4 (1%)
Pathological Q-wave 7 (2%) 1 (0.3%
24-h Holter findings 311 311
Minimum heart rate (beats/min) 60 1 54 1
Mean heart rate (beats/min) 81 2 73 1
Maximum heart rate (beats/min) 128 1 122 1
Total AF 22 (7%) 4 (1%)
Persistent AF 16 (5%) 3 (1%)
Paroxysmal AF 6 (2%) 1 (0.3%
Single ventricular ectopics 316 92 128 31
Single atrial ectopics* 47 9 66 16
240 ventricular ectopics 29 (9%) 26 (8%)
240 atrial ectopics* 16 (5%) 14 (5%)
Ventricular salvoes 8 (3%) 2 (1%)
Atrial salvoes* 69 (23%) 40 (14%)
Supraventricular tachycardia* 3 (1%) 3 (1%)
Nonsustained ventricular tachycardia 5 (2%) 0
Second- or third-degree block 1 (0.2%) 0
ll values expressed as n (%) or mean  SEM. *Excluding persistent atrial fibrillation (AF) on Holts. 21%, p  0.0001), especially congestive cardiac failure a23% vs. 2%, p  0.0001). Measurements of BP at presen-
ation were higher among those with AF than without
147  5 mm Hg vs. 136  1 mm Hg, p  0.02 and 83 
mm Hg vs. 75  1 mm Hg, p  0.005); those with AF
howed a greater prevalence of LVH on ECG (11% vs. 1%,
 0.001). Factors independently predicting AF at pre-
entation of hyperthyroidism were increasing age (p 
.0001), history of cardiac failure (p  0.0001), diabetes
p 0.02), elevated systolic or diastolic BP (p 0.005), and
VH on ECG (p  0.02).
The outcome of subjects with AF in terms of rhythm is
hown in Figure 1. Seven of the 8 with previously known
F remained in AF. Of the 15 patients with newly
iagnosed persistent AF, 10 remained in AF (6 rendered
uthyroid, 4 with suppressed TSH) and 5 reverted to sinus
hythm (all rendered euthyroid). Of the 6 with PAF, only
had PAF at follow-up (all rendered euthyroid). Four
atients underwent electrical cardioversion once euthyroid:
maintained sinus rhythm at follow-up, and 2 achieved
inus rhythm only transiently (1 prescribed verapamil, 1 no
rug therapy). Electrical cardioversion was declined by 5
because of age or general frailty, median age 75 years, IQR
3 to 79 years) and not offered to 5 on clinical grounds
dilated atria on ECG and/or known permanent AF). The
ajority of AF patients were commenced on warfarin (n 
4, 83%); 5 received aspirin because of contraindications or
efusal to take warfarin.
Overall, of the 29 patients with AF, 11 successfully
ts With Matched Controls
hyroid Patients With Matched Controls
Cohort Without Vascular Disease
p Value
Thyroid
n  265
Control
n  265 p Value
0.0001 6 (2%) 1 (0.4%) 0.1
0.6 6 (2%) 9 (3%) 0.6
0.1 2 (1%) 0 0.5
0.9 3 (1%) 5 (2%) 0.7
0.6 0 1 (0.4%) 0.9
0.1 0 0 0.9
206 206
0.0001 59 1 53 1 0.0001
0.0001 82 2 76 2 0.03
0.0001 129 2 124 1 0.02
0.001 6 (3%) 2 (1%) 0.3
0.009 5 (2.5%) 1 (0.5%) 0.2
0.1 1 (0.5%) 1 (0.5%) 0.9
0.06 109 48 114 35 0.9
0.3 31 10 52 18 0.3
0.8 11 (5%) 15 (7%) 0.6
0.9 7 (4%) 8 (4%) 0.9
0.1 3 (1%) 2 (1%) 0.9
0.001 37 (18%) 20 (10%) 0.03
0.9 3 (1%) 0 0.3
0.1 3 (1%) 0 0.3
0.2 0 0 0.9
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.9 weeks after recruitment), 4 on rate/rhythm drug therapy
19.8  6.1 weeks after recruitment; 3 sotalol, 1 verapamil),
nd 2 electrically cardioverted (neither on concomitant
ntiarrhythmic therapy). These patients were younger than
hose remaining in AF (68.0 years, IQR 63 to 74 years vs.
5.0 years, IQR 72 to 79 years, p  0.006) and more likely
o have been rendered initially hypothyroid by antithyroid
rug therapy (defined as serum TSH 5.5 mU/l and low
ree T4) compared with those remaining in AF (58% vs.
3%, p  0.02). Independent predictors of successful
eversion to sinus rhythm were lower systolic BP (p  0.02)
nd an initial hypothyroid state induced by antithyroid
herapy (p  0.009). Age, gender, biochemical severity of
yperthyroidism, smoking history, known vascular disease,
nd diabetes were not predictive. Seven patients with AF
ied during follow-up of congestive cardiac failure (n  1),
erebrovascular accident (n  1), ischemic heart disease (n 
), malignant neoplasm (n  2), and septicemia (n  2).
ortality data at follow-up. After a mean follow up of
6.6  0.6 months, 26 patients died compared with 12
ontrol subjects (p  0.01). The causes of death among
atients were malignancy (n  7), ischemic heart disease
n 5), cerebrovascular disease (n 1), aortic stenosis (n
), sepsis (n 10), carbon monoxide poisoning (n 1), and
astrointestinal bleed (n  1). Causes of death among
omparison of Electrocardiogram and Holter Data Between Patientith Biochemical Sub linical Hyperthyr idism During Follow-Up Wi
Table 5 Comparison of Electrocardiogram and Holter Data BetwWith Biochemical Subclinical Hyperthyroidism During F
Electrocardiogram Findings
Total Coho
Thyroid
n  109
Control
n  109
AF 8 (7%) 1 (1%)
Abnormal cardiac axis 5 (5%) 5 (5%)
Left ventricular hypertrophy 0 0
Right bundle branch block 2 (2%) 2 (2%)
Left bundle branch block 1 (1%) 2 (2%)
Pathological Q-wave 0 0
24-h Holter findings 85 85
Minimum heart rate (beats/min) 57 1 54 1
Mean heart rate (beats/min) 78 2 76 2
Maximum heart rate (beats/min) 122 3 122 1
Total AF 5 (6%) 1 (1%)
Persistent AF 4 (5%) 1 (1%)
Paroxysmal AF 1 (1%) 0
Single ventricular ectopics 87 26 170 48
Single atrial ectopics* 28 8 101 36
240 ventricular ectopics 8 (9%) 9 (11%
240 atrial ectopics* 3 (4%) 5 (6%)
Ventricular salvoes 0 0
Atrial salvoes* 14 (17%) 13 (16%
Supraventricular tachycardia* 3 (4%) 2 (2%)
Nonsustained ventricular tachycardia 4 (5%) 0
Second- or third-degree block 0 0
ll values expressed as n (%) or mean  SEM. *Excluding persistent atrial fibrillation (AF) on Holtontrol subjects were malignancy (n  7), ischemic heart oisease (n  2), acute aortic dissection (n  1), sepsis (n 
), and aortic stenosis (n  1).
After excluding all subjects with known vascular disease,
0 patients died during follow-up compared with 3 control
ubjects (p  0.09). The causes of death among patients
ere sepsis (n  4), ischemic heart disease (n  1), aortic
tenosis (n  1), malignancy (n  3), and carbon monoxide
oisoning (n  1); causes of death among euthyroid control
ubjects were malignancy (n  1), sepsis (n  1), and acute
ortic dissection (n  1).
iscussion
vert hyperthyroidism is associated with cardiovascular
ymptoms and changes in cardiovascular hemodynamics (1),
hich were confirmed by the present study. However, data
n the effect of antithyroid therapy on these findings are
parse and generally reflect small studies (18–20). We
howed that despite restoration of biochemical euthyroid-
sm, previously hyperthyroid patients continue to experience
ignificant cardiovascular symptoms, in particular palpita-
ion, dyspnea, and cough. Symptoms persist even in those
ithout a preceding history of vascular disease. A recent
tudy found a high prevalence of pulmonary hypertension in
yperthyroidism, which was corrected after treatment (21).
he dyspnea reported in overt hyperthyroidism in part may
e the result of elevated pulmonary pressure. Low efficiency
tched Controls
Patients
-Up With Matched Controls
Cohort Without Vascular Disease
p Value
Thyroid
n  71
Control
n  71 p Value
0.0001 3 (4%) 0 0.3
0.9 2 (3%) 3 (4%) 0.9
0.9 0 0 0.9
0.9 1 (1%) 1 (1%) 0.9
0.9 0 0 0.9
0.9 0 0 0.9
57 57
0.002 58 2 56 1 0.2
0.7 81 3 79 2 0.5
0.9 127 4 124 2 0.5
0.001 3 (5%) 0 0.3
0.01 3 (5%) 0 0.3
0.1 0 0 0.9
0.2 45 21 27 9 0.4
0.2 14 7 48 25 0.2
0.8 3 (5%) 2 (4%) 0.9
0.6 1 (2%) 3 (5%) 0.6
0.9 0 0 0.9
0.9 5 (9%) 4 (7%) 0.9
0.4 2 (4%) 0 0.5
0.1 2 (4%) 0 0.5
0.9 0 0 0.9
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yperthyroidism and may also explain this symptom (20);
hese changes were found to be reversible with treatment in
he latter study.
In the present study, hyperthyroid patients showed a
ignificant postural decrease in systolic BP suggesting an
bnormality of peripheral vascular resistance, this finding
eing absent in the cohort of hyperthyroid subjects without
nown vascular disease after antithyroid therapy. A marked
ecrease in peripheral vascular resistance has been reported
n overt hyperthyroidism, but the mechanism remains un-
ertain (1). A recent study showed excessive endothelial
itric oxide production and enhanced sensitivity of the
ndothelium in overt hyperthyroidism, and suggested that
ascular endothelium may be a specific target for thyroid
ormones (22). The persistent postural decrease in systolic
P despite restoration of biochemical euthyroidism re-
orted here implies ongoing abnormalities of vascular en-
othelial function. Two recent studies have suggested ab-
ormal endothelial function in overt hyperthyroidism,
ersisting even after effective treatment by antithyroid
herapy (23,24); in contrast, Napoli et al. (22) found
bnormal endothelial function in overt hyperthyroidism
orrected after restoration of euthyroidism. Dehydration
nd deconditioning as a cause of the orthostatic changes in
P were considered unlikely because changes in vascular
omparison of Electrocardiogram and Holter Data Betweenatients Rendered Euthyroid at Follow-Up With Matched Controls
Table 6 Comparison of Electrocardiogram and Holter Data BetwPatients Rendered Euthyroid at Follow-Up With Matche
Electrocardiogram Findings
Total Coho
Thyroid
n  206
Contro
n  206
AF 10 (5%) 2 (1%)
Abnormal cardiac axis 8 (4%) 9 (5%)
Left ventricular hypertrophy 3 (2%) 0
Right bundle branch block 2 (1%) 6 (3%)
Left bundle branch block 1 (0.5%) 1 (0.5%
Pathological Q-wave 1 (0.5%) 0
24-h Holter findings 133 133
Minimum heart rate (beats/min) 54 1 54 1
Mean heart rate (beats/min) 76 2 72 2
Maximum heart rate (beats/min) 120 1 122 2
Total AF 4 (3%) 1 (1%)
Persistent AF 3 (2%) 1 (1%)
Paroxysmal AF 1 (1%) 0
Single ventricular ectopics 103 57 171 5
Single atrial ectopics* 25 6 62 2
240 ventricular ectopics 7 (5%) 15 (11%
240 atrial ectopics* 5 (4%) 5 (4%)
Ventricular salvoes 0 1 (1%)
Atrial salvoes* 24 (18%) 19 (15%
Supraventricular tachycardia* 4 (3%) 2 (2%)
Nonsustained ventricular tachycardia 0 0
Second or third-degree block 1 (1%) 0
ll values expressed as n (%) and mean  SEM. *Excluding persistent atrial fibrillation (AF) on Hoesistance are well described in hyperthyroidism, none of the rubjects were clinically dehydrated, and all were ambulatory
t investigation.
After sinus tachycardia, AF is the most common dys-
hythmia in hyperthyroidism with incidence increasing with
ge (1,25,26). The prevalence of AF in our hyperthyroid
ohort was 7.3%; previous studies have reported prevalences
f 5% to 15%, but these have mostly been small (27) and
etrospective in design (25,26). A recent large but retrospec-
ive study of hyperthyroid subjects found a prevalence of
F/atrial flutter of 8.3% (28), in keeping with the present
tudy. Treatment of hyperthyroidism has been reported in
ne study to lead to spontaneous reversion to sinus rhythm
n nearly two-thirds of patients within 8 to 10 weeks with
irtually none reverting spontaneously beyond 3 months
29). In our study, most PAF resolved (evaluated on Holter
onitoring) when patients became euthyroid, but newly
iagnosed persistent AF resolved in only 5 of 15 cases;
reviously known AF resolved rarely (1 of 8 cases). An older
tudy found the rate of spontaneous reversion was higher in
he young and in men, whereas the presence of congestive
ardiac failure adversely affected reversion to sinus rhythm
26). We found that those reverting to sinus rhythm were
ounger and that almost all had newly diagnosed AF.
nown vascular disease, gender, and serum-free T4 at
resentation did not affect the likelihood of reversion. An
nitial hypothyroid state independently predicted successful
ntrols
Cohort Without Vascular Disease
p Value
Thyroid
n  133
Control
n  133 p Value
0.05 1 (1%) 0 0.9
0.9 5 (4%) 5 (4%) 0.9
0.3 2 (2%) 0 0.5
0.3 0 4 (3%) 0.2
0.9 0 1 (1%) 0.9
0.9 0 0 0.9
85 85
0.9 55 1 54 1 0.4
0.1 79 3 76 3 0.3
0.4 123 2 125 2 0.5
0.8 1 (1%) 0 0.9
0.6 1 (1%) 0 0.9
0.9 0 0 0.9
0.4 26 10 126 51 0.06
0.1 13 5 61 34 0.2
0.1 5 (6%) 9 (11%) 0.1
0.9 1 (1%) 3 (4%) 0.6
0.9 0 1 (1%) 0.9
0.7 11 (13%) 11 (13%) 0.9
0.6 2 (3%) 0 0.5
0.9 0 0 0.9
0.9 0 0 0.9
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romptly hypothyroid (30); this hypothyroid state may be
mportant in reducing tissue concentrations of thyroid
ormones and facilitating a return to sinus rhythm, suggest-
ng that those with AF and hyperthyroidism should be
ctively rendered hypothyroid in the short term, if tolerated,
n an attempt to facilitate reversion to sinus rhythm.
The T3-responsive genes encode both structural and
egulatory proteins in the heart, such as myosin heavy chain,
arcoplasmic reticulum calcium adenosine triphosphatase,
eta-adrenoceptors, sodium-potassium adenosine triphos-
hatase, and voltage gated potassium channels (1). Whether
hanges in these genes persist after antithyroid therapy and
ontribute to persisting AF remains to be evaluated. Thy-
oid hormone also affects extranuclear sites in the cardiac
yocyte, influencing primarily the transport of amino acids,
ugars, and calcium across the cell membrane (31,32). The
3 can also alter the function of a number of ion channels
n the cell membrane directly (including sodium, potassium,
nd calcium), and potentially can predispose to the devel-
pment of AF (33). All of these effects of thyroid hormones
re likely to have an influence on electrical remodeling of the
yocardium.
Supraventricular dysrhythmias were prevalent in overt
yperthyroidism (regardless of its etiology) and persisted
uring antithyroid therapy; they are known to initiate AF in
Figure 1 Treatment and Outcome of Hyperthyroid Patients With
AF  atrial fibrillation; PAF  paroxysmal atrial fibrillation.ome patients (34). There are a few studies involving small cumbers of subjects using Holter monitoring to determine
he prevalence of dysrhythmias in hyperthyroid patients
15). Ventricular dysrhythmias were not more prevalent in
yperthyroidism in the present study, a finding consistent
ith previous small studies (15,35). The pathophysiology of
upraventricular and ventricular arrhythmias differs in mul-
iple respects, but the reason for the discrepancy observed in
yperthyroidism remains unclear. We evaluated treated
yperthyroid patients after a relatively short period after
estoration of biochemical euthyroidism. Further longer-
erm follow-up of the cohort will help clarify whether
ardiovascular manifestations noted after antithyroid ther-
py persist in the longer term and specifically whether this
ersistence might contribute to the long-term morbidity
nd mortality that we and others have shown in previous
tudies (3–5).
Subclinical hyperthyroidism is increasingly recognized as
aving significant consequences on the cardiovascular sys-
em, with increased morbidity (36,37) and mortality (38).
hose with subclinical hyperthyroidism during follow-up in
he present study had persisting cardiovascular symptoms
nd hemodynamic disturbances, even after those with vas-
ular disease were excluded. These persisting abnormalities
ay reflect the preceding overt thyroid hormone excess and
delay in restoration of complete biochemical (or tissue)
ormality despite restoration of circulating thyroid hormoneAFoncentrations to normal. The present findings are in
k
e
r
s
o
d
f
s
b
S
t
e
a
e
s
b
s
t
h
s
A
t
e
p
s
v
C
m
i
a
h
A
A
T
T
t
R
D
B
B
b
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
80 Osman et al. JACC Vol. 49, No. 1, 2007
Cardiovascular Manifestations of Hyperthyroidism January 2/9, 2007:71–81eeping with those of previous studies evaluating both
ndogenous (39,40) and T4-induced subclinical hyperthy-
oidism (41–43), although these studies generally examined
ubclinical hyperthyroidism of a greater duration than that
bserved during treatment of overt hyperthyroidism. En-
ogenous subclinical hyperthyroidism is known to be a risk
actor for subsequent development of AF (36,37), but
tudies evaluating other dysrhythmias in these patients have
een small and have had conflicting findings (39,40).
tudy limitations. Some of the differences noted between
he hyperthyroid and control cohorts may have been influ-
nced by recruitment and ascertainment bias. However, we
ttempted to minimize these effects by recruiting an uns-
lected consecutive hyperthyroid cohort representing all
ubjects with the diagnosis referred to a specialist clinic and
y recruiting control subjects from a variety of sources. The
imilarity of covariates between the hyperthyroid and con-
rol cohorts suggests that the observed differences reflect the
yperthyroid state. Although the current study found per-
isting cardiovascular abnormalities, such as symptoms and
F, this was after a relatively short period of follow-up and
hese differences may not be sustained. Although a differ-
nce in mortality for the 2 groups was shown after a longer
eriod of follow-up, the number of deaths remained too
mall to determine whether excess mortality was specifically
ascular in nature.
onclusions. Cardiovascular symptoms and signs, abnor-
al hemodynamics, and cardiac dysrhythmias are common
n overt hyperthyroidism, and furthermore, these persist
fter antithyroid therapy has restored the circulating thyroid
ormone concentration to normal. Risk factors predicting
F associated with hyperthyroidism were identified.
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